What's included CJC-1295 No DAC + Ipamorelin 2 pens 5/10mg Tesamorelin 10mg 6 vials DSIP 5mg 1 vial Obesity metabolic syndrome insulin resistance GLP-1 / GIP Option A Semaglutide CellGenic anchors with Semaglutide and pairs AOD-9604 and MOTS-C to address obesity, metabolic syndrome, and insulin resistance
We offer - Wegovy injection from 159/month
TriNetX cohort study (547,993 matched adults, published in JAAD International, 2026): GLP1 users were 40 percent more likely to develop nonscarring hair loss, 64 percent more likely to develop pattern thinning, and 76 percent more likely to experience stress-related shedding
The key is finding a high-quality product that your body can actually use effectively
Following the FDA's proposed ban on 503B bulk compounding of GLP-1s in April 2026, patient-specific compounding through licensed 503A pharmacies remains the legally compliant pathway